Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
The Zhitong Finance App learned that Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
According to the news, Pacific Securities released a research report saying that as of December 2023, there have been more than 20 domestic ADC overseas transactions, and the transaction amount has exceeded 35 billion US dollars. Once again, Chinese pharmaceutical companies have become the protagonists of innovation. The bank believes that Chinese pharmaceutical companies are very good at engineering innovation. The space that can be modified by ADC is far greater than that of other types of innovative drugs. In the future, ADC will become a conventional weapon for cancer treatment, and the golden age of ADC has just begun.
Huajin Securities said earlier that overseas licensing transactions for domestic ADCs are hot, and their innovative R&D capabilities have been widely recognized by foreign pharmaceutical companies. It is recommended to focus on the deployment of next-generation ADC technology platforms, innovative pharmaceutical companies that anticipate successful ADC going overseas/overseas, and innovative ADC CDMO pharmaceutical companies, such as Dongyao Pharmaceutical.